SS-31

Overview

SS-31, also known as Elamipretide (formerly MTP-131 and Bendavia), is a synthetic mitochondria-targeted tetrapeptide developed by Hazel H. Szeto and Peter W. Schiller, from whom it derives its "SS" designation. First described in 2004, SS-31 represents one of the most clinically advanced mitochondria-targeted therapeutics, having progressed through Phase 1 and Phase 2 trials and currently in Phase 3 clinical development for Barth syndrome, a rare X-linked mitochondrial disorder.

The sequence of SS-31 is: D-Arg-Dmt-Lys-Phe-NH2 (where Dmt is 2',6'-dimethyltyrosine)

SS-31 is uniquely designed to concentrate within the inner mitochondrial membrane (IMM), where it selectively binds to cardiolipin, a phospholipid critical for the structural organization and function of the electron transport chain (ETC). By stabilizing cardiolipin interactions with ETC complexes, SS-31 improves mitochondrial efficiency, reduces electron leak, and decreases the production of harmful reactive oxygen species (ROS) at their primary source.

Key Characteristics

• Origin: Rational drug design by Szeto and Schiller (2004)
• Classification: Mitochondria-targeted tetrapeptide
• Molecular Weight: 640.77 g/mol
• Clinical Stage: Phase 3 (Barth syndrome); Phase 2 (primary mitochondrial myopathy, heart failure)
• FDA Designations: Fast Track, Orphan Drug, Rare Pediatric Disease
• Unique Feature: Concentrates 1000-5000x in mitochondria relative to cytoplasm

Mechanism

SS-31 operates through a highly targeted mechanism centered on the inner mitochondrial membrane and its essential lipid component, cardiolipin.

Primary Mechanisms

1. Cardiolipin Binding and Stabilization

The central mechanism of SS-31 involves direct interaction with cardiolipin:

• Selective Accumulation: SS-31's alternating aromatic-cationic motif (positive charge, aromatic ring, positive charge, aromatic ring) enables it to concentrate within the IMM at 1000-5000x cytoplasmic concentrations
• Cardiolipin Interaction: Binds directly to cardiolipin through electrostatic and hydrophobic interactions
• ETC Complex Stabilization: Cardiolipin is required for the proper assembly and function of ETC Complexes I, III, IV, and V (ATP synthase). SS-31 stabilizes these cardiolipin-complex interactions
• Cristae Remodeling: Promotes proper cristae morphology, the folds of the IMM where ETC complexes reside

2. Electron Transport Chain Optimization

Through cardiolipin stabilization, SS-31 improves ETC function:

• Reduces electron leak at Complexes I and III (primary sites of superoxide generation)
• Improves coupling efficiency between electron transport and ATP synthesis
• Restores normal membrane potential in dysfunctional mitochondria
• Enhances overall ATP production capacity

3. ROS Reduction at Source

Unlike conventional antioxidants that scavenge ROS after formation:

• SS-31 prevents excessive ROS generation at the ETC by reducing electron leak
• Does not eliminate all ROS (which are needed for cellular signaling)
• Normalizes rather than eliminates oxidative stress
• This "source-targeted" approach distinguishes SS-31 from general antioxidants

Cellular Effects

At the cellular level, SS-31 has been shown to:

• Improve mitochondrial membrane potential in damaged cells
• Restore ATP production in mitochondrially compromised tissues
• Reduce mitochondrial swelling and cytochrome c release (anti-apoptotic)
• Protect cardiolipin from oxidative damage and remodeling
• Preserve cristae ultrastructure under stress conditions
• Enhance cellular oxygen consumption efficiency

Research

Barth Syndrome

Human Studies (TAZPOWER Trial)

The primary clinical development indication:

• Barth syndrome is caused by mutations in the tafazzin gene, leading to defective cardiolipin remodeling
• Phase 2 TAZPOWER trial showed improvements in 6-minute walk test distance
• Cardiac function measures (stroke volume, cardiac output) showed improvement trends
• Subjective quality of life and fatigue scores improved
• Phase 3 trial (TAZPOWER-3) is enrolling for confirmatory data
• FDA granted Rare Pediatric Disease designation

Cardiac Ischemia-Reperfusion Injury

Animal Studies

Extensive preclinical cardiac research:

• Reduced myocardial infarct size by 40-60% in rodent ischemia-reperfusion models
• Preserved left ventricular function after acute coronary occlusion
• Reduced cardiac fibrosis and remodeling in chronic models
• Protected cardiac mitochondria from ischemic damage

Human Studies

• Phase 2a trial in patients undergoing percutaneous coronary intervention showed trends toward reduced cardiac biomarker release
• EMBRACE STEMI trial in ST-elevation myocardial infarction showed a non-significant trend toward reduced infarct size
• Ongoing investigation for heart failure with reduced ejection fraction

Primary Mitochondrial Myopathy

Clinical Data

• Phase 2 trial showed improvements in 6-minute walk test distance in patients with primary mitochondrial myopathy
• Exercise tolerance and fatigue measures showed improvement
• Muscle biopsy markers of mitochondrial function improved in some subjects

Age-Related Mitochondrial Decline

Animal Studies

Research on aging models:

• SS-31 improved cardiac function in aged mice to levels comparable to young adults
• Skeletal muscle mitochondrial function improved in aged animals
• Reduced age-related increase in mitochondrial ROS production
• Improved exercise capacity in aged mice
• Kidney function preservation in aging models

Kidney Injury

Preclinical Data

• Protected against ischemia-reperfusion kidney injury in multiple animal models
• Reduced acute kidney injury severity in cisplatin-induced nephrotoxicity
• Preserved renal mitochondrial function and tubular cell viability

Dosing

Research Protocols

Based on available research literature and clinical trial data:

Administration Notes

Subcutaneous Injection

• Primary route in clinical trials for chronic administration
• Clinical trial dose: 40 mg subcutaneous daily
• Rotate injection sites (abdomen, thigh, upper arm)
• Consistent daily timing recommended

Intravenous

• Used in acute settings (cardiac surgery, kidney injury trials)
• Weight-based dosing: 0.05 mg/kg/hr infusion in some protocols
• Requires medical supervision

Reconstitution

When using lyophilized SS-31:

• Use bacteriostatic water or sterile water for reconstitution
• Store reconstituted peptide refrigerated (2-8C)
• Relatively stable peptide; use within 28 days
• SS-31 is more chemically stable than many peptides due to D-amino acid and amidated C-terminus

Pharmacokinetics

Absorption

• Subcutaneous: Near-complete absorption (~100% bioavailability)
• Intravenous: Complete immediate bioavailability
• Tmax: Approximately 30 minutes subcutaneously
• Absorption is rapid and consistent across injection sites

Distribution

• Concentrates 1000-5000x within mitochondria relative to cytoplasm
• The alternating cationic-aromatic structure drives IMM accumulation
• Achieves therapeutic concentrations in cardiac, skeletal muscle, renal, and neural tissue
• Does not require a carrier or targeting moiety -- structure is inherently mitochondria-seeking

Metabolism

• Partially metabolized by tissue peptidases
• The D-Arg residue at the N-terminus confers resistance to aminopeptidases
• C-terminal amidation provides additional protease resistance
• Both modifications contribute to the relatively long half-life for a tetrapeptide

Elimination

• Half-life: Approximately 4 hours (plasma)
• Partial renal clearance of intact peptide
• Mitochondrial residence time likely exceeds plasma half-life
• Steady state achieved within 2-3 days of daily dosing
• No significant accumulation at recommended doses

Synergy & Stacking

SS-31 is commonly considered alongside other mitochondrial-targeting compounds and general health peptides.

Common Combinations

SS-31 + MOTS-c

Comprehensive mitochondrial support:

• SS-31 provides structural support (cardiolipin stabilization, ETC optimization)
• MOTS-c provides functional signaling (AMPK activation, mitochondrial biogenesis)
• Together they address both the integrity of existing mitochondria and the production of new ones
• No known antagonistic interactions

SS-31 + CoQ10

Complementary ETC support:

• CoQ10 functions as an electron carrier between Complexes I-II and Complex III
• SS-31 stabilizes the protein complexes themselves via cardiolipin
• Different points of intervention in ETC function
• CoQ10 is well-established and widely available

SS-31 + NAD+ Precursors (NMN/NR)

Aging-focused combination:

• NAD+ precursors support sirtuin activity and mitochondrial gene expression
• SS-31 optimizes existing mitochondrial function
• Complementary approaches to mitochondrial aging

Timing Considerations

• Daily administration at a consistent time
• No significant food interaction known
• Can be administered at any time of day
• When combining with exercise, pre-exercise dosing may provide acute mitochondrial protection

Safety

Known Side Effects

SS-31's safety profile is relatively well-characterized from clinical trials:

Common (mild)

• Injection site reactions (erythema, pain, induration)
• Headache
• Nausea (generally mild and transient)

Uncommon

• Dizziness
• Fatigue (paradoxically, in some subjects)
• Mild renal function changes at high doses

Not Observed at Standard Doses

• No cardiac arrhythmias
• No significant hepatotoxicity
• No immunosuppression
• No hormonal disruption

Contraindications

Avoid or use with extreme caution if:

• Severe renal impairment (eGFR < 30 mL/min)
• Known hypersensitivity to SS-31 or modified amino acids
• Pregnant or breastfeeding
• Under 18 years of age outside of clinical trial settings

Drug Interactions

Based on clinical trial and preclinical data:

• Nephrotoxic drugs (may impair SS-31 clearance)
• No significant CYP450 interactions expected
• May be protective when co-administered with mitochondria-damaging drugs (doxorubicin, cisplatin)
• No known interactions with common cardiac medications

Monitoring

Baseline Assessments

Before starting any SS-31 protocol:

• Renal function (creatinine, BUN, eGFR)
• Liver function tests
• Complete blood count
• Cardiac biomarkers if indicated (BNP, troponin)
• 6-minute walk test or other functional capacity measure
• Echocardiogram if cardiac indication is the focus

During Use

• Renal function at 2 and 4 weeks, then monthly
• Monitor for injection site reactions
• Track functional capacity (exercise tolerance, fatigue scores)
• Cardiac monitoring if used for cardiac indications
• Subjective quality of life assessment

Post-Protocol

• Repeat renal function tests
• Reassess functional capacity
• Cardiac imaging if relevant
• Document response trajectory for future protocol planning
• Note any decline in function after discontinuation

Regulatory

Current Status

Legal Considerations

• Under active clinical development by Stealth BioTherapeutics (now Larimar Therapeutics)
• Available from research chemical suppliers, but quality may differ from pharmaceutical grade
• Not a controlled substance
• Not currently prohibited in sports
• FDA and EMA have both granted orphan designations, reflecting recognized therapeutic potential

Future Outlook

• Phase 3 trials for Barth syndrome ongoing
• Potential additional indications: primary mitochondrial myopathy, heart failure, acute kidney injury, age-related decline
• If approved for Barth syndrome, it would be the first cardiolipin-targeted therapy
• Broader mitochondrial disease applications may follow approval for initial indication
• The "source-targeted antioxidant" concept may inspire next-generation compounds

References